Bli Corp offers a platform of collaborative cyber‑physical AI agents that automate and integrate the design‑make‑test‑analyze (DMTA) workflow for advanced formulations and devices in the bioeconomy. By linking disparate systems such as ELN/LIMS, CAD/CAM, MES and ERP, the platform creates a continuous, data‑driven loop that reduces manual trial‑and‑error and speeds product development for health and environmental applications.
Funding
$1.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Product development in the bioeconomy relies on separate tools for design, manufacturing, testing, and analysis (e.g., ELN/LIMS, CAD/CAM, MES, ERP). Data must be manually transferred between these systems, preventing continuous knowledge accumulation and causing slow, trial‑and‑error cycles.
Solution
BLI delivers a unified cyber‑physical platform that overlays existing enterprise stacks with collaborative AI agents. These agents orchestrate the full Design‑Make‑Test‑Analyze (DMTA) loop, automatically routing data across tools and triggering downstream actions without manual handoffs. Integrated connectors link to ELN/LIMS, CAD/CAM, MES, ERP, QMS, and CRM systems, while connected robotic hardware (BioLoom bioprinter and MetaLab formulation lab) executes the “Make” and “Test” steps. A shared intelligence layer records outcomes, updates predictive models, and provides versioned, audit‑ready digital recipes that feed back into subsequent design iterations. The platform supports a five‑level autonomy framework, allowing teams to start with assisted workflows and progress toward fully autonomous labs. Security and compliance features (SOC 2, ISO 27001, GDPR‑ready) ensure data integrity across the lifecycle.
Target Audience
Primary users are scientists, R&D engineers, and IT staff who author experimental workflows, as well as process engineers, manufacturing leads, lab managers, and quality‑assurance personnel who run and monitor autonomous experiments. The platform also serves regulatory and innovation leaders in life sciences, pharma, and consumer/industrial bio‑innovation organizations.
Features
- Visual graph authoring environment (Loominus Studio IDE) for composing AI agents, skills, and instrument integrations
- AI‑driven agents that plan, schedule, and execute long‑horizon DMTA workflows across heterogeneous tools
- Pre‑built connectors for ELN/LIMS, CAD/CAM, MES, ERP, QMS, and CRM enabling seamless data flow
- Connected robotic hardware: BioLoom multi‑tool bioprinter and MetaLab self‑driving formulation lab
- Shared intelligence layer that captures experiment results, updates foundation‑model predictions, and maintains a searchable knowledge base
- Full audit trail, version control, and compliance modules (SOC 2, ISO 27001, GDPR) for regulated environments
- Scalable autonomy framework with five levels from assisted operation to full self‑driving labs
- Optional cloud project storage and real‑time team collaboration tools (in development)